GUIDELINES FOR SELECTING ADJUVANT THERAPY IN EARLY BREAST CANCER

 

 

 

NCCN

The only assay recognized to predict the benefit of adjuvant chemotherapy and the only assay classified as “recommended” in postmenopausal patients with N0/N1, HR+, HER2- breast cancer.

 

 

 

 

 

 

 

 

ASCO
The only test strongly recommended for all N0 and postmenopausal N1 patients with ER+, HER2- early breast cancer.
The recommendation is independent of clinical risk, with high quality evidence.